IL33 and COVID-19: In particular, it provided evidence of preferential MC trajectories in diseases such as COPD/PF, dominated by late alarmin/pro‐fibrotic responses, and IFNγ/IL‐33 inflammation in COVID‐19, which further corroborate and expand our knowledge of the pathogenic mechanisms involving MCs in disease [47, 93].